ArticleHIV medicine2025
Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment-experienced people living with HIV: A feasibility survey.
Article in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionAs life expectancy among persons with HIV on antiretroviral therapy (ART) is increasing, comorbidities and polypharmacy increase. Drug-drug interactions (DDIs) are common among persons with HIV with a history of virological failure, since many are receiving boosted ART. We assessed the willingness of individuals with a history of virological failure on a boosted ART to participate in simplification trials and evaluated their expectations towards ART.
methodsWe conducted a cross-sectional survey among persons with HIV at five hospitals in Switzerland between October 2021 and July 2022. We collected data using quantitative paper-based questionnaires and analysed the data using descriptive statistics. Community representatives were involved in the study planning and conduct, and in the interpretation of findings.
resultsOverall, 143 (64%) of 223 eligible persons with HIV participated. Median age was 59 years (interquartile range [IQR] 52.5-63.5), 32 (22%) were female, median time on ART was 26 years (IQR: 20-27). Among participants, 104 (72%) would agree to participate in clinical trials aiming at evaluating simplified ART regimens with reduced DDI risks, or were still undecided. Of them, 92 (88%) were satisfied with their current treatment. Their main expectations about simplified ART were treatment efficacy (91%), fewer DDIs (83%), low pill number (78%) and forgiveness in case of missed doses (75%).
conclusionsPersons with HIV and a history of virological failure were motivated to participate in clinical research. This underlines the importance of including them in future trials. Furthermore, conducting feasibility surveys and including persons with HIV in the study design prior to trials ensures their relevance and alignment with people's needs and expectations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.